clinical trial · NCT07308132
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Janssen Research & Development, LLC·phase1·recruiting·n = 130
Lymphoma, Non-HodgkinJNJ-95566692JNJ-87801493
brief summary
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) at the putative RP2D(s) (Part 2: Dose Expansion).
started
Jan 20, 2026
primary completion
Aug 31, 2028
completion
Aug 31, 2028
last updated
Apr 13, 2026
official title
A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol